Trial site
Westfaelische Wilhelms-Universitaet Muenster
Muenster, 48149, GermanyNot linked to an institution yet
- 19running trials
- 14closed trials
The trials here
What the 33 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 29 trials
- Phase 1/24 trials
- Phase 43 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Completed14 trials
- Active, not recruiting13 trials
- Recruiting6 trials
- Lead sponsor
- Merck Sharp & Dohme LLC4 trials
- Dr. Inge Winter3 trials
- Boehringer Ingelheim2 trials
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)2 trials
- Sanofi2 trials
- and 19 more
Running trials
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973786· Phase 3· Dr. Inge Winter· Source
Active, not recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973851· Phase 3· Dr. Inge Winter· Source
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875· Phase 4· Dr. Inge Winter· Source
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775· Phase 1/2· Miltenyi Biomedicine GmbH· Source
Recruiting
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492· Phase 3· Jena University Hospital· Source
Recruiting
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
NCT06482684· Phase 2· Christian Schmidt, MD· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· Phase 3· AbbVie· Source
Active, not recruiting
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
NCT05551299· Phase 4· University of Leipzig· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Active, not recruiting
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source
Recruiting
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
2023-504880-18-00· Phase 1/2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Active, not recruiting
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
NCT03206671· Phase 3· University Hospital Muenster· Source
Recruiting
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia
2023-504694-20-00· Phase 1/2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihistamines
2023-505446-25-00· Phase 1/2· Jasper Therapeutics Inc.· Source
Terminated
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-505558-16-00· Phase 3· Almirall S.A.· Source
Completed
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· Phase 3· Amgen Inc.· Source
Completed
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
2022-502040-13-00· Phase 2· University of Leipzig· Source
Completed
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· Phase 2· LEO Pharma· Source
Completed
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· Phase 2· Sanofi· Source
Completed
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT05916365· Phase 3· Almirall, S.A.· Source
Completed
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580· Phase 2· Boehringer Ingelheim· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357· Phase 1· Genmab· Source
Active, not recruiting
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
NCT04597125· Phase 4· Bayer· Source
Completed
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231749· Phase 3· Bristol-Myers Squibb· Source
Report an error